Literature DB >> 24094029

Increased serum prolactin levels in drug-naive first-episode male patients with schizophrenia.

Yakup Albayrak1, Murat Beyazyüz, Elmas Beyazyüz, Murat Kuloğlu.   

Abstract

BACKGROUND: Prolactin is a hormone receiving considerable attention in psychiatry. Increased serum prolactin level is frequently associated with dopamine blocking antipsychotics. Furthermore, decreased prolactin level was considered a reflector of the effect of antipsychotics. However, there is restricted numbers of investigations that researched baseline prolactin levels in first-episode patients with schizophrenia. AIMS: We purpose to investigate serum baseline prolactin levels in drug-naive first-episode patients with schizophrenia (FES) and to explore the differences in serum prolactin levels between FES, drug-free schizophrenic patients (DFS) and healthy controls (HC).
MATERIAL AND METHODS: The study was conducted in the Departments of Psychiatry, Gölbaşı Hasvak and Kırklareli State Hospitals, Turkey. Thirty male FES, 41 male DFS and 32 male HC were included in study. All participants were clinically examined and individually interviewed. Before initiating any pharmacological treatment, 5 ml of venous blood was collected to measure serum prolactin levels between 08:00 and 10:00 h, which was determined by radioimmunoassay (RIA). Prolactin levels were also collected from the consenting HC using the same assay.
RESULTS: The mean age was higher in the DFS group. The mean score of Brief Psychiatric Rating Scale was higher in the FES group and mean score of Scale for the Assessment of Negative Symptoms was higher in the DFS group. The mean value of prolactin was higher in the FES group (34.1 ± 19.9 ng/dl) compared with DFS (17.9 ± 6.5 ng/dl) and HC (9.7 ± 2.3 ng/dl) (F = 35.5, P < 0.001). Additionally, the mean value of serum prolactin is higher in the DFS group compared with HC (P < 0.001).
CONCLUSION: To our knowledge, this study is the first to demonstrate higher serum prolactin levels in male FES compared with male DFS and male HC. Prolactin might act as a protective factor while first episode of schizophrenia is experienced. Future studies are needed to provide the role of prolactin in schizophrenia.

Entities:  

Keywords:  Drug-free; Drug-naive; First episode; Prolactin; Schizophrenia

Mesh:

Substances:

Year:  2013        PMID: 24094029     DOI: 10.3109/08039488.2013.839739

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  7 in total

1.  Prolactin, flupenthixol decanoate and first episode schizophrenia - clinical and laboratory correlates.

Authors:  Mari Retief; Bonginkosi Chiliza; Lebogang Phahladira; Robin Emsley; Laila Asmal
Journal:  Metab Brain Dis       Date:  2019-08-17       Impact factor: 3.584

Review 2.  Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus.

Authors:  Yutaka Mizuki; Shinji Sakamoto; Yuko Okahisa; Yuji Yada; Nozomu Hashimoto; Manabu Takaki; Norihito Yamada
Journal:  Int J Neuropsychopharmacol       Date:  2021-05-18       Impact factor: 5.176

3.  Involvement of miR-106b in tumorigenic actions of both prolactin and estradiol.

Authors:  Kuan-Hui Ethan Chen; Karissa Bustamante; Vi Nguyen; Ameae M Walker
Journal:  Oncotarget       Date:  2017-05-30

4.  Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia.

Authors:  Fuyin Yang; Lan Chen; Xinyu Fang; Ke Zheng; Cheng Zhu; Chaoqun Xu; Chen Zhang; Wei Tang
Journal:  Neuropsychiatr Dis Treat       Date:  2018-12-13       Impact factor: 2.570

Review 5.  Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction.

Authors:  Kah Kheng Goh; Cynthia Yi-An Chen; Tzu-Hua Wu; Chun-Hsin Chen; Mong-Liang Lu
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

6.  Cell Surface Protein mRNAs Show Differential Transcription in Pyramidal and Fast-Spiking Cells as Revealed by Single-Cell Sequencing.

Authors:  Lilla Ravasz; Katalin Adrienna Kékesi; Dániel Mittli; Mihail Ivilinov Todorov; Zsolt Borhegyi; Mária Ercsey-Ravasz; Botond Tyukodi; Jinhui Wang; Tamás Bártfai; James Eberwine; Gábor Juhász
Journal:  Cereb Cortex       Date:  2021-01-05       Impact factor: 5.357

Review 7.  Dopamine-prolactin pathway potentially contributes to the schizophrenia and type 2 diabetes comorbidity.

Authors:  C Gragnoli; G M Reeves; J Reazer; T T Postolache
Journal:  Transl Psychiatry       Date:  2016-04-19       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.